2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-106499
    Sulfinalol 66264-77-5 98%
    Sulfinalol is an orally active β-adrenoceptor antagonist with direct vasodilator activity.
    Sulfinalol
  • HY-106500
    Pacrinolol 65655-59-6 98%
    Pacrinolol (HOE 224) is a selective and orally active beta1 adrenergic receptor blocker. Pacrinolol can inhibit Isoprenaline (HY-108353)-induced positive inotropic effect and increased heart rate. Pacrinolol can be used for the research of cardiovascular disease.
    Pacrinolol
  • HY-106523
    Nipradolol 81486-22-8 98%
    Nipradolol (KT-210; K-351) is a potent blocker of alpha-1-adrenergic receptors. Nipradolol inhibits the increase of intraocular pressure (IOP) in an albino rabbit model induced by Phenylephrine (HY-B0769). Nipradolo suppresses the noradrenaline (NA)-induced muscles contraction, also exhibits vasodilator activity on the dog coronary artery.
    Nipradolol
  • HY-106554
    Trimazosin 35795-16-5 98%
    Trimazosin is an orally active, quinazoline derivative which is structurally related to prazosin. Trimazosin shows hypotensive effect by selectively block α1-adrenoceptors.
    Trimazosin
  • HY-106559
    Sorbinicate 6184-06-1 98%
    Sorbinicate, a derivative of nicotinic acid, exerts a favourable influence on blood rheology and platelet function.
    Sorbinicate
  • HY-10655A
    Palosuran hydrochloride 2469274-58-4 98.67%
    Palosuran hydrochloride (ACT-058362 hydrochloride) is a potent, selective, and orally active antagonist of urotensin II receptor, with an IC50 of 3.6 nM for CHO cell membranes expressing human recombinant receptors. Palosuran hydrochloride can improves pancreatic and renal function in diabetic rats.
    Palosuran hydrochloride
  • HY-106561
    Tioclomarol 22619-35-8 98%
    Tioclomarol, a coumarin anticoagulant, is a vitamin K antagonist.
    Tioclomarol
  • HY-106565
    Meproscillarin 33396-37-1 98%
    Meproscillarin (Methylproscillaridin) is a glycoside. Meproscillarin can be used for research of heart failure.
    Meproscillarin
  • HY-106580
    Plafibride 63394-05-8 98%
    Plafibride (ITA 104) is an orally active hypolipemic, platelet aggregation inhibitor.
    Plafibride
  • HY-10664R
    SB-611812 (Standard) 345892-71-9 98%
    SB-611812 (Standard) is the analytical standard of SB-611812. This product is intended for research and analytical applications. SB-611812 is a urotensin II receptor (UTR) antagonist with the potential in the research of cardiovascular disease.
    SB-611812 (Standard)
  • HY-106688
    Alinidine 33178-86-8 98%
    Alinidine (St-567) is a specific bradycardic agent. Alinidine reduces the slope of the diastolic depolarization in sinoatrial tissue and Purkinje fibers. Alinidine shows antiischemic and antiarrhythmic effects.
    Alinidine
  • HY-106694
    Acitemate 101197-99-3 98%
    Acitemate is an anti-lipemic agent.
    Acitemate
  • HY-106718
    Barucainide 79784-22-8 98%
    Barucainide is an Ib-class anti-arrhythmic agent (moderately blocking sodium channel). Barucainide exhibits concentration-dependent inhibitory effects on the maximum upstroke velocity (Vmax) of Purkinje fibers and ventricular muscle in dogs. Barucainide significantly shortens the action potential duration (APD). Barucainide significantly inhibits the pacemaker activity frequency of atrial tissue in rabbits and the enhanced automaticity of Purkinje fibers under normal resting potential in response to isoproterenol. Barucainide cannot inhibit the abnormal automaticity emission frequency of canine Purkinje fibers induced by barium. Barucainide can be used for research on arrhythmias.
    Barucainide
  • HY-106754
    FLM-5011 50652-76-1 98%
    FLM-5011 is a lipoxygenase inhibitor. FLM-5011 can diminish myocardial ischaemia injury and shows anti-inflammatory effect. FLM-5011 can be used for the researches of inflammation and cardiovascular disease, such as myocarditis.
    FLM-5011
  • HY-106761
    Oxodipine 90729-41-2 98%
    Oxodipine, a dihydropyridine-type calcium antagonist, inhibits KCl-induced aortic contraction in rabbits and reduces cardiac force in less potent rat ventricular test-paper contractions. In rat cultured neonatal ventricular myocytes, Oxodipine reduces L-type Ca currents (I) with an IC50 of 0.24 μM, and against T-type Ca currents (I) with an IC50 of 0.41 μM. Oxodipine causes constipation in mice and gingival hyperplasia in dogs.
    Oxodipine
  • HY-106790
    Nileprost 71097-83-1 98%
    Nileprost is a prostacyclin analogue. Nileprost is a mixed type PGI2/PGE2 agonist. Nileprost can be studied in research on acute myocardial ischemia.
    Nileprost
  • HY-106797
    CV 3611 98829-12-0 98%
    CV 3611 is a potent and orally active free radical scavenger. CV 3611 shows anti-inflammatory, antiarrhythmic and anticancer effects. CV 3611 can be used for the researches of cancer, inflammation and cardiovascular disease, such as hepatocellular carcinoma and acute pancreatitis.
    CV 3611
  • HY-106798
    Nemazoline hydrochloride 111073-18-8 98%
    Nemazoline hydrochloride (A-57219 hydrochloride) is selective α-adrenergic agent with α1-agonist/α2-antagonist activity, which is used as a nasal decongestant. Nemazoline hydrochloride produces decongestion by α1-mediated contraction of capacitance vessels, but not compromises blood flow by virtue of α2-antagonism. Nemazoline hydrochloride also blocks endogenous noradrenaline-mediated α 2-constriction of the resistance vessels.
    Nemazoline hydrochloride
  • HY-106804
    MS 857 107189-96-8 98%
    MS 857 is an orally active nonglycoside and nonsympathomimetic cardiotonic agent. MS 857 exhibits cardiac and coronary vasodilator effect.
    MS 857
  • HY-106816
    Ceronapril 111223-26-8 98%
    Ceronapril (SQ 29852) is a potent and orally active angiotensin converting enzyme (ACE) inhibitor with an IC50 of 36 nM.
    Ceronapril
Cat. No. Product Name / Synonyms Application Reactivity